Viral Hepatitis Prevention Board Hanoi, 25–26 July 2018

Hexavalent Vaccines: Hepatitis B antibody response and co-administration with other vaccines

Prof. Timo Vesikari Vaccine Research Center University of Tampere Tampere, Finland

Academic Expertise in Vaccine Research





Timo Vesikari Conflicts of Interest

PI in several study protocols on

Infanrix Hexa (GSK) Hexaxim/Hexyon (SP-MSD) Vaxelis or PR5I (Merck)

Consultant to GSK 2016

Member (Chair) of SP-MSD Advisory Board for Pediatric Vaccines until 2017

Consultant to Merck on PR5I until 2017

Landscape

Infanrix hexa (GSK) (GSK)



- gold standard
- requires reconstitution of lyophilized Hib component
- Hexyon / Hexacim (Sanofi Pasteur)



- fully liquid
- Vaxelis (Merck) 😒 MERCK
- gully liquid

Real differences in immunogenicity between the vaccines are minor or non-existent

Infanrix hexa™ (GSK)

Clever trade name implying that this is the basic vaccine for infants

Hexaxim / Hexyon® (Sanofi Pasteur)

Vaxelis® (Merck)

Runner-ups for trade name and substance





Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and *Haemophilus* type b conjugate vaccine (adsorbed)



Comparison of pertussis components in hexavalent vaccines

Vaxelis 5 PT, FHA, PRN, FIM2,3
Infanrix hexa 3 PT, FHA, PRN
Hexyon 2 PT, FHA

No known difference in clinical protection against pertussis

Aluminum adjuvant in hexavalent vaccines

	Al+++ per dose
Vaxelis	0.3 mg
Hexyon	0.6 mg
Infanrix hexa	0.8 mg


Clinical experience with Infanrix hexa

Antibody	SP cut-off	% SP subjects
Anti-D	0.1 IU/ml	≥ 98.0
Anti-T	0.1 IU/ml	≥ 99.6
Anti-HBs	10 mIU/ml	≥ 96.8
Anti-polio 1	1:8	≥ 99.4
Anti-polio 2	1:8	≥ 95.7
Anti-polio 3	1:8	≥ 98.8
Anti-PRP	0.15 µg/ml	\geq 91.7 (2 doses)
		≥ 96.4 (3 doses)

All schedules combined. Data from *Infanrix™ hexa* European SPC


Kilpi TM et al. Hum Vaccine 2009;5:18–25.







Infanrix hexa[™] induced long-lasting immune memory against HBV



Time since hexavalent vaccination, years

^aDefined as subjects with an anti-HBsAg titre ≥10 mIU/mI; ^bNumber of subjects with available results (pre-booster;post-challenge) HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus

1. Giambi et al. BMC Infect Dis 2008;8:100; 2. Steiner et al. BMC Infect Dis 2010;10:9; 3. Zinke et al. Hum Vaccin 2009;5(9):592–598; 4. Zanetti et al. Lancet Infect Dis 2010;10(11):755–761

Infanrix hexa™: Established use

Infanrix hexa[™] has extensive evidence supporting its use, encompassing >10 years of clinical practice and >15 years in clinical studies^{1–3}


In the decade following licensure, *Infanrix hexa*[™] was administered in over 100 GSK-sponsored interventional studies with 27 500 infants receiving *Infanrix hexa*[™] as a primary vaccine, and over 21 000 children receiving a booster dose

As of the end of December 2012, over 90 million doses of *Infanrix hexa*™ have been distributed worldwide, helping to protect children in 95 countries against six serious childhood diseases^{4,5}




Infanrix hexa[™] can be used in a two-dose primary and booster vaccination schedule¹

A number of countries recommend the use of a 2dose primary and booster vaccination schedule, including:²



Infanrix hexa[™] can be given with other vaccines

Infanrix hexa[™] can be co-administered with the following vaccines:^{1–12}



In general, co-administration does not meaningfully impact on the immunogenicity of any of the vaccine components^{13–18}

Hexyon

- Unique hexavalent vaccine in a fully liquid, ready-to-use formulation
- Indicated for primary and booster vaccination of infants and toddlers from 6 weeks to 24 months of age combining:
 - Well-established antigens (D,T, aP, IPV, Hib) used in combined Sanofi Pasteur MSD vaccines as Pentavac

Hexyon

– New hepatitis B antigen





A new hepatitis B antigen specifically developed for Hexyon

Produced using the patented *Hansenula polymorpha* yeast expression system:

 Consistent high quality and reliable supply^{1,2}

Compliant with European Pharmacopoeia Monograph 2067³

Manufactured and controlled in Sanofi Pasteur's state-of-the-art facility in Argentina⁴

 Completely dedicated to this new hepatitis B antigen⁴

Produced exclusively for use in Hexyon⁴




*This facility passed a GMP inspection by the French Agency (on behalf of the EMA and the WHO) in February 2012.

^{1.} Celik E et al. Biotechnol Adv, 2012;30(5):1108–1118; 2. Shouval D et al. J Hepatol, 2003;39(Suppl1):S70–S76. 3. European Public Assessment Report for Hexyon: EMA/137344; EMEA/H/C/002796. Last accessed October 2013. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002796/WC500145760.pdf. Last accessed October 2013; 4. Sanofi Pasteur MSD, data on file, 2013.

Hexyon vs DTaP-HBV-IPV/Hib (Infanrix Hexa™): Hepatitis B immune responses

1 month post-primary vaccination (2, 4, 6 months)*[†]



* Primary vaccination at 2, 4 and 6 months. Measurements made 1 month post-primary vaccination series.

⁺ A3L11 and A3L17 participants did not receive hepatitis B vaccination at birth, whereas all A3L12 and A3L24 participants received hepatitis B vaccination at birth.

1. Becerra A et al. Vaccine 2012;30:6492–6500. 2. Kosalaraska P et al. Int J Infect Dis. 2011;15(4):e249–e256. 3. Lanata C et al. Vaccine and Vaccination 2012;3:1. 4. López P et al. Poster presented at the Congress ICID: 13–16 June 2012. DTaP-HBV-IPV/Hib (Infanrix hexa[®])

Co-administration of Hexyon/Hexaxim[™] or Infanrix Hexa[™] with Prevnar13

Schedule 3, 5, 11–12 months Finland and Sweden

Protocol A3L38 Sanofi Pasteur

Vesikari T, et al. PIDJ 2017;36:87–93.

Hepatitis B responses

	Hexyon N=248	Infanrix hexa N=249
Seroconversion after 3 doses		
≥10 mIU/mL ≥100 mIU/mL	96.4 % 91.2 %	99.6% 98.0%
GMT		
Pre-dose 3 Post-dose 3	76.5 (62.0,94.4) 1370 (1069,1757)	260 (218,311) 5015 (4178,6020)

Vesikari T, et al. PIDJ 2017;36:87–93.

Protocol A3L38 Responses to Prevnar13 after 3 doses

	Hexyon N=249	Infanrix hexa N=248
Serotype 3	86.3 %	88.0 %
Serotype 5	95.1 %	98.1 %
All other serotypes	98.2–100 %	98.1–100 %

Vesikari T, et al. PIDJ 2017;36:87–93.

Hexyon/Hexacim co-administration with RV vaccine (Rotarix) at 2 and 4 months of age

Rotavirus IgA antibody responses		
	Hexyon	Infanrix hexa
Seroconversion	77.9 % (71.1,83.7)	86.9 % (75.8,94.2)
GMC	110 (85.4,142)	155 (96.6,250)
	"Cimilar"	

"Similar"

Lopez P, et al. PIDJ 2017;36:e272–e282.

Hexyon co-administration with MenC at 2 and 4 months of age

Men C responses ≥8 SBA After dose 1 99.4% After dose 2 100% GMC

After dose 1885 (737,1063)After dose 2580 (505,664)

MenC vaccine can be given together with Hexyon One dose is as good as two (or better)

Vesikari T, et al. Vaccine 2017;35(3):452-458.

Hexyon / Hexacima / Hexaxim is registered in 98 countries



- A fully liquid ready-to-use, preservative free hexavalent paediatric vaccine
- Indicated for primary (3 doses) and booster vaccination of infants and toddlers from six weeks to 24 months of age against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b
- Should be in accordance with official recommendations
- Marketing authorisation granted by the European Commission [30 countries] on 17 April 2013 [http://ec.europa.eu/health/documents/community-register/html/h829.htm]
- Marketing authorisation granted in Latin America [Peru, Chile, Guatemala, Mexico, Paraguay, Argentina, El Salvador, Uruguay], Asia [Malaysia, Philippines], Africa [South Africa], Greater Europe [Georgia, Kazakhstan]




Marketing Autorisation granted

EC Decision 15-FEB-2016

C Confidential

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003982/human med 001962.jsp&mid=WC0b01ac058001d124

http://ec.europa.eu/health/documents/community-register/html/h1079.htm



Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and *Haemophilus* type b conjugate vaccine (adsorbed)

Property of MCM Partnership (VAXELIS)

Vaxelis (PR5I) is a unique combination of wellestablished antigens from vaccines licensed in EU or US

		Antigen(s)	Amounts	Licensed vaccine containing the same antigen(s)
Ρ	Merck	PRP-OMPC Polyribosylribitol phosphate polysaccharide coupled to the outer membrane complex of <i>Neisseria meningitidis</i>	3 µg	PedvaxHIB (US)
R	Increa	HBsAg ² Recombinant hepatitis B surface antigen	10 µg	HBVaxPro RECOMBIVAX HB (US)
5	Sanofi Pasteur	5 component acellular pertussis ¹ PT: Pertussis Toxoid FHA: Filamentous Haemagglutinin PRN: Pertactin FIM: Fimbriae Types 2 and 3 Diphtheria Toxoid ¹ Tetanus Toxoid ¹	20 μg 20 μg 3 μg 5 μg ≥20 IU ≥40 IU	PENTACEL (US) PEDIACEL
I		IPV Inactivated Poliovirus Type 1 Type 2 Type 3	40-D 8-D 32-D	IMOVAX POLIO PENTAVAC, HEXYON PEDIACEL

Aluminium used as adjuvant

(1 adsorbed on aluminium phosphate (0.17 mg Al³⁺), ² adsorbed on amorphous aluminium hydroxyphosphate sulfate (0.15 mg Al³⁺))

Protocol V419-007 (Vaxelis) 3+1 schedule at 2, 3, 4 and 12 months


PR5I (Vaxelis) vs. Infanrix hexa

PR5I was non-inferior for all immunogenicity comparisons

PRP responses 1 month after infant series

% with titer ≥0.15µg/ml PR5I 98% Infanrix hexa 87% Group difference 11.4% (8.4, 14.7) "Significant"

Non-inferiority of Vaxelis versus Infanrix hexa demonstrated for the 3+1 schedule (007)



Pertussis response:

If pre-vaccination antibody concentration was < 4x lower limit of quantification (LLOQ), then the post-vaccination antibody concentration was $\geq 4x$ LLOQ;

if pre-vaccination antibody concentration was ≥ 4xLLOQ,

then the post-vaccination antibody concentration was ≥ pre-vaccination levels

<u>HepB</u>: ≥ 10mlU/mL <u>Polio</u>: ≥ 1:8 dil


Post Toddler dose:

- High response rates for all PR5I antigens (≥95%)
- non-inferiority to Infanrix hexa regarding the response rates to HepB and pertussis antigens

Vesikari T et al, 33rd ESPID, May12-16,2015, Leipzig, Germany V419-007 CSR

vaccines for life

Non-inferiority of Vaxelis versus Infanrix hexa demonstrated for the 2+1 schedule (008)



Summary of Response Rates Post Toddler Dose

*If pre-vaccination antibody concentration was <LLOQ, then the post-vaccination antibody concentration was ≥LLOQ; If pre-vaccination antibody concentration was ≥LLOQ, then the post-vaccination antibody concentration was ≥prevaccination levels (the prevaccination level was defined as the antibody titer at pre-Dose 1)

Note: Control (INFANRIX™hexa) does not contain FIM antigens. Error bars represent 95% CI.

Post Toddler dose:

- High response rates for all PR5I antigens
- · non-inferiority to Infanrix hexa demonstrated regarding the response rates to all PR5I antigens



Silfverdal SA, et al. Vaccine 2016;34:3810–6.

Vaxelis vs. Infanrix hexa Coadministration with routine pediatric vaccines in the US (2, 4, 6 months)

	Vaxelis N=522	Infanrix hexa N=274
RV IgA GMC	282	277

GMC ratio 1.02 (0.83 to 1.24)

Marshall GS, et al. Pediatrics 2015;136:e323–e332.

Booster dose at 12 months of Vaxelis *vs.* Infanrix hexa given concomitantly with MMRV

	Vaxelis N=467	Infanrix hexa N=474
Measles	96.2%	96.4%
Mumps	94.9%	91.8%
Rubella	98.3%	97.9%
Varicella	97.6%	97.7%

Conclusion: Vaxelis can be given concurrently with MMRV

Conclusions for HepB in hexavalent vaccines

- AntiHBs responses to various hexavalent vaccines are not equal (highest after Infanrix hexa)
- High primary responses are associated with better persistence
- AntiHBs responses may be (simply) correlated with the quantity of Al⁺⁺⁺ adjuvant in hexavalent vaccine

Conclusions on coadministration of other childhood vaccines with hexavalent vaccines

- No interference with pneumococcal conjugate vaccine one way or the other
- No significant suppression of RV IgA response after vaccination
- No suppression of MenC response
- No interference with MMRV



UNIVERSITY OF TAMPERE Finland

Thank you!



